Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 1/2010

01.01.2010 | Original Paper

Comparative in silico analyses and experimental validation of novel splice site and missense mutations in the genes MLH1 and MSH2

verfasst von: Beate Betz, Stephan Theiss, Murat Aktas, Carolin Konermann, Timm O. Goecke, Gabriela Möslein, Heiner Schaal, Brigitte Royer-Pokora

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Hereditary non-polyposis colorectal cancer, an autosomal dominant predisposition to colorectal cancer and other malignancies, is caused by inactivating mutations of DNA mismatch repair genes, mainly MLH1 and MSH2. Missense mutations affect protein structure or function, but may also cause aberrant splicing, if located within splice sites (ss) or cis-acting sequences of splicing regulatory proteins, i.e., exonic splicing enhancers or exonic splicing silencers. Despite significant progress of ss scoring algorithms, the prediction for the impact of mutations on splicing is still unsatisfactory. For this study, we assessed ten ss and nine missense mutations outside ss in MLH1 and MSH2, including eleven newly identified mutations, and experimentally analyzed their effect at the RNA level. We additionally tested and compared the reliability of several web-based programs for the prediction of splicing outcome for these mutations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Arnold S, Buchanan DD, Barker M, Jaskowski L, Walsh MD, Birney G, Woods MO, Hopper JL, Jenkins MA, Brown MA, Tavtigian SV, Goldgar DE, Young JP, Spurdle AB (2009) Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. Hum Mutat 30:757–770CrossRefPubMed Arnold S, Buchanan DD, Barker M, Jaskowski L, Walsh MD, Birney G, Woods MO, Hopper JL, Jenkins MA, Brown MA, Tavtigian SV, Goldgar DE, Young JP, Spurdle AB (2009) Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. Hum Mutat 30:757–770CrossRefPubMed
Zurück zum Zitat Asang C, Hauber I, Schaal H (2008) Insights into the selective activation of alternatively used splice acceptors by the human immunodeficiency virus type-1 bidirectional splicing enhancer. Nucleic Acids Res 36:1450–1463CrossRefPubMed Asang C, Hauber I, Schaal H (2008) Insights into the selective activation of alternatively used splice acceptors by the human immunodeficiency virus type-1 bidirectional splicing enhancer. Nucleic Acids Res 36:1450–1463CrossRefPubMed
Zurück zum Zitat Auclair J, Buisine MP, Navarro C, Ruano E, Montmain G, Desseigne F, Saurin JC, Lasset C, Bonadona V, Giraud S, Puisieux A, Wang Q (2006) Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. Hum Mutat 27(2):145–154CrossRefPubMed Auclair J, Buisine MP, Navarro C, Ruano E, Montmain G, Desseigne F, Saurin JC, Lasset C, Bonadona V, Giraud S, Puisieux A, Wang Q (2006) Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. Hum Mutat 27(2):145–154CrossRefPubMed
Zurück zum Zitat Buratti E, Chivers M, Kralovicova J, Romano M, Baralle M, Krainer AR, Vorechovsky I (2007) Aberrant 5′ splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res 35:4250–4263CrossRefPubMed Buratti E, Chivers M, Kralovicova J, Romano M, Baralle M, Krainer AR, Vorechovsky I (2007) Aberrant 5′ splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res 35:4250–4263CrossRefPubMed
Zurück zum Zitat Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR (2003) ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31:3568–3571CrossRefPubMed Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR (2003) ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31:3568–3571CrossRefPubMed
Zurück zum Zitat Fairbrother WG, Yeh RF, Sharp PA, Burge CB (2002) Predictive identification of exonic splicing enhancers in human genes. Science 297:1007–1013CrossRefPubMed Fairbrother WG, Yeh RF, Sharp PA, Burge CB (2002) Predictive identification of exonic splicing enhancers in human genes. Science 297:1007–1013CrossRefPubMed
Zurück zum Zitat Freund M, Asang C, Kammler S, Konermann C, Krummheuer J, Hipp M, Meyer I, Gierling W, Theiss S, Preuss T, Schindler D, Kjems J, Schaal H (2003) A novel approach to describe a U1 snRNA binding site. Nucleic Acids Res 31:6963–6975CrossRefPubMed Freund M, Asang C, Kammler S, Konermann C, Krummheuer J, Hipp M, Meyer I, Gierling W, Theiss S, Preuss T, Schindler D, Kjems J, Schaal H (2003) A novel approach to describe a U1 snRNA binding site. Nucleic Acids Res 31:6963–6975CrossRefPubMed
Zurück zum Zitat Goren A, Ram O, Amit M, Keren H, Lev-Maor G, Vig I, Pupko T, Ast G (2006) Comparative analysis identifies exonic splicing regulatory sequences—the complex definition of enhancers and silencers. Mol Cell 22:769–781CrossRefPubMed Goren A, Ram O, Amit M, Keren H, Lev-Maor G, Vig I, Pupko T, Ast G (2006) Comparative analysis identifies exonic splicing regulatory sequences—the complex definition of enhancers and silencers. Mol Cell 22:769–781CrossRefPubMed
Zurück zum Zitat Gorlov IP, Gorlova OY, Frazier ML, Amos CI (2003) Missense mutations in hMLH1 and hMSH2 are associated with exonic splicing enhancers. Am J Hum Genet 73:1157–1161CrossRefPubMed Gorlov IP, Gorlova OY, Frazier ML, Amos CI (2003) Missense mutations in hMLH1 and hMSH2 are associated with exonic splicing enhancers. Am J Hum Genet 73:1157–1161CrossRefPubMed
Zurück zum Zitat Hartmann L, Theiss S, Niederacher D, Schaal H (2008) Diagnostic of pathogenic splicing mutations: does bioinformatics cover all bases? Front Biosci 13:3252–3272CrossRefPubMed Hartmann L, Theiss S, Niederacher D, Schaal H (2008) Diagnostic of pathogenic splicing mutations: does bioinformatics cover all bases? Front Biosci 13:3252–3272CrossRefPubMed
Zurück zum Zitat Kohonen-Corish M, Ross VL, Doe WF, Kool DA, Edkins E, Faragher I, Wijnen J, Kahn PM, Macrae F, St John DJM (1996) RNA-based mutation screening in hereditary nonpolyposis colorectal cancer. Am J Hum Genet 59:818–824PubMed Kohonen-Corish M, Ross VL, Doe WF, Kool DA, Edkins E, Faragher I, Wijnen J, Kahn PM, Macrae F, St John DJM (1996) RNA-based mutation screening in hereditary nonpolyposis colorectal cancer. Am J Hum Genet 59:818–824PubMed
Zurück zum Zitat Kralovicova J, Vorechovsky I (2007) Global control of aberrant splice-site activation by auxiliary splicing sequences: evidence for a gradient in exon and intron definition. Nucleic Acids Res 35:6399–6413CrossRefPubMed Kralovicova J, Vorechovsky I (2007) Global control of aberrant splice-site activation by auxiliary splicing sequences: evidence for a gradient in exon and intron definition. Nucleic Acids Res 35:6399–6413CrossRefPubMed
Zurück zum Zitat Lastella P, Surdo NC, Resta N, Guanti G, Stella A (2006) In silico and in vivo splicing analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects. BMC Genomics 7:243CrossRefPubMed Lastella P, Surdo NC, Resta N, Guanti G, Stella A (2006) In silico and in vivo splicing analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects. BMC Genomics 7:243CrossRefPubMed
Zurück zum Zitat Lynch HT, de la Chapelle A (1999) Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 36:801–818PubMed Lynch HT, de la Chapelle A (1999) Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 36:801–818PubMed
Zurück zum Zitat Madsen PP, Kibak M, Roca X, Sachidanandam R, Krainer AR, Christensen E, Steiner RD, Gibson KM, Corydon TJ, Knudsen I, Wanders RJA, Ruiter JPN, Gregersen N, Storstein-Andresen B (2006) Short/branched-chain acyl-CoA dehydrogenase deficiency due to an IVS + 3A > G mutation that causes exon skipping. Hum Genet 118:680–690CrossRefPubMed Madsen PP, Kibak M, Roca X, Sachidanandam R, Krainer AR, Christensen E, Steiner RD, Gibson KM, Corydon TJ, Knudsen I, Wanders RJA, Ruiter JPN, Gregersen N, Storstein-Andresen B (2006) Short/branched-chain acyl-CoA dehydrogenase deficiency due to an IVS + 3A > G mutation that causes exon skipping. Hum Genet 118:680–690CrossRefPubMed
Zurück zum Zitat Mangold E, Pagenstecher C, Friedl W, Mathiak M, Buettner R, Engel C, Loeffler M, Hollinski-Feder E, Muller-Koch Y, Keller G, Schackert HK, Krüger S, Goecke T, Moeslein G, Kloor M, Gebert J, Kunstmann E, Schulmann K, Ruschoff J, Propping P (2005) Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1721 German families suspected of hereditary nonpolyposis colorectal cancer. Int J Cancer 116:692–702CrossRefPubMed Mangold E, Pagenstecher C, Friedl W, Mathiak M, Buettner R, Engel C, Loeffler M, Hollinski-Feder E, Muller-Koch Y, Keller G, Schackert HK, Krüger S, Goecke T, Moeslein G, Kloor M, Gebert J, Kunstmann E, Schulmann K, Ruschoff J, Propping P (2005) Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1721 German families suspected of hereditary nonpolyposis colorectal cancer. Int J Cancer 116:692–702CrossRefPubMed
Zurück zum Zitat Ohno K, Brengman JM, Felice KJ, Cornblath DR, Engel AG (1999) Congenital end-plate acetylcholinesterase deficiency caused by a nonsense mutation and an A > G splice-donor-site mutation at position +3 of the collagenlike-tail-subunit gene (COLQ): how does G at position +3 result in aberrant splicing? Am J Hum Genet 65:635–644CrossRefPubMed Ohno K, Brengman JM, Felice KJ, Cornblath DR, Engel AG (1999) Congenital end-plate acetylcholinesterase deficiency caused by a nonsense mutation and an A > G splice-donor-site mutation at position +3 of the collagenlike-tail-subunit gene (COLQ): how does G at position +3 result in aberrant splicing? Am J Hum Genet 65:635–644CrossRefPubMed
Zurück zum Zitat Pagenstecher C, Wehner M, Friedl W, Rahner N, Aretz S, Friedrichs N, Sengteller M, Henn W, Buettner R, Propping P, Mangold E (2005) Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants. Hum Genet. doi:10.1007/s00439-005-0107-8 Pagenstecher C, Wehner M, Friedl W, Rahner N, Aretz S, Friedrichs N, Sengteller M, Henn W, Buettner R, Propping P, Mangold E (2005) Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants. Hum Genet. doi:10.​1007/​s00439-005-0107-8
Zurück zum Zitat Sahashi K, Masuda A, Matsuura T, Shinmi J, Zhang Z, Takeshima Y, Matsuo M, Sobue G, Ohno K (2007) In vitro and in silico analysis reveals an efficient algorithm to predict the splicing consequences of mutation at the 5′ splice sites. Nucleic Acids Res 35:5995–6003CrossRefPubMed Sahashi K, Masuda A, Matsuura T, Shinmi J, Zhang Z, Takeshima Y, Matsuo M, Sobue G, Ohno K (2007) In vitro and in silico analysis reveals an efficient algorithm to predict the splicing consequences of mutation at the 5′ splice sites. Nucleic Acids Res 35:5995–6003CrossRefPubMed
Zurück zum Zitat Shapiro MB, Senapathy P (1987) RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 15:7155–7174CrossRefPubMed Shapiro MB, Senapathy P (1987) RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 15:7155–7174CrossRefPubMed
Zurück zum Zitat Sharp A, Pichert G, Lucassen A, Eccles D (2004) RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1. Hum Mutat 24:272 (Mutation in Brief #738 Online)CrossRefPubMed Sharp A, Pichert G, Lucassen A, Eccles D (2004) RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1. Hum Mutat 24:272 (Mutation in Brief #738 Online)CrossRefPubMed
Zurück zum Zitat Smith PJ, Zhang C, Wang J, Chew SL, Zhang MQ, Krainer AR (2006) An increased specificity score matrix fort he prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 15:2490–2508CrossRefPubMed Smith PJ, Zhang C, Wang J, Chew SL, Zhang MQ, Krainer AR (2006) An increased specificity score matrix fort he prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 15:2490–2508CrossRefPubMed
Zurück zum Zitat Tournier I, Vezain M, Martins A, Charbonnier F, Baert-Desurmont S, Olschwang S, Wang Q, Buisine MP, Soret J, Tazi J, Frébourg T, Tosi M (2008) A large fraction on unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects. Hum Mutat 29:1412–1424CrossRefPubMed Tournier I, Vezain M, Martins A, Charbonnier F, Baert-Desurmont S, Olschwang S, Wang Q, Buisine MP, Soret J, Tazi J, Frébourg T, Tosi M (2008) A large fraction on unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects. Hum Mutat 29:1412–1424CrossRefPubMed
Zurück zum Zitat Vorechovsky I (2006) Aberrant 3′ splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res 34:4630–4641CrossRefPubMed Vorechovsky I (2006) Aberrant 3′ splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res 34:4630–4641CrossRefPubMed
Zurück zum Zitat Wang Z, Rolish ME, Yeo G, Tung V, Mawson M, Burge CB (2004) Systematic identification and analysis of exonic splicing silencers. Cell 119:831–845CrossRefPubMed Wang Z, Rolish ME, Yeo G, Tung V, Mawson M, Burge CB (2004) Systematic identification and analysis of exonic splicing silencers. Cell 119:831–845CrossRefPubMed
Zurück zum Zitat Wimmer K, Roca X, Beiglböck H, Callens T, Etzler J, Rao AR, Krainer AR, Fonatsch C, Messiaen L (2007) Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5′ splice-site disruption. Hum Mutat 28:599–612CrossRefPubMed Wimmer K, Roca X, Beiglböck H, Callens T, Etzler J, Rao AR, Krainer AR, Fonatsch C, Messiaen L (2007) Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5′ splice-site disruption. Hum Mutat 28:599–612CrossRefPubMed
Zurück zum Zitat Yeo G, Burge CB (2004) Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 11:377–394CrossRefPubMed Yeo G, Burge CB (2004) Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 11:377–394CrossRefPubMed
Zurück zum Zitat Zhang XHF, Chasin LA (2004) Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev 18:1241–1250CrossRefPubMed Zhang XHF, Chasin LA (2004) Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev 18:1241–1250CrossRefPubMed
Metadaten
Titel
Comparative in silico analyses and experimental validation of novel splice site and missense mutations in the genes MLH1 and MSH2
verfasst von
Beate Betz
Stephan Theiss
Murat Aktas
Carolin Konermann
Timm O. Goecke
Gabriela Möslein
Heiner Schaal
Brigitte Royer-Pokora
Publikationsdatum
01.01.2010
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2010
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-009-0643-z

Weitere Artikel der Ausgabe 1/2010

Journal of Cancer Research and Clinical Oncology 1/2010 Zur Ausgabe

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.